Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
- Conditions
- Metastatic Gastrointestinal Carcinoid TumorPulmonary Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell Carcinoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00093782
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00086840
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
- Conditions
- Gastrointestinal Stromal TumorRecurrent Adult Soft Tissue SarcomaStage I Adult Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00087074
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Previously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesRecurrent Adult Acute Lymphoblastic LeukemiaSecondary Myelodysplastic Syndromes
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00084916
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 1236
- Registration Number
- NCT00083993
CCI-779 in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00012142
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00079235
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00079456
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
- First Posted Date
- 2004-01-19
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00076206
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00075647
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.